Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1747923

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1747923

Rotavirus Vaccines

PUBLISHED:
PAGES: 277 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Rotavirus Vaccines Market to Reach US$15.9 Billion by 2030

The global market for Rotavirus Vaccines estimated at US$9.7 Billion in the year 2024, is expected to reach US$15.9 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2024-2030. Rotarix Vaccines, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Rotateq Vaccines segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.2% CAGR

The Rotavirus Vaccines market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global "Rotavirus Vaccines" Market - Key Trends & Drivers Summarized

Why Is Rotavirus Vaccination So Vital in Pediatric Healthcare?

Rotavirus remains one of the leading causes of severe diarrheal disease in infants and young children worldwide, despite major advances in sanitation and nutrition. The virus is highly contagious, and once symptomatic, often requires hospitalization due to dehydration. Rotavirus vaccines offer the most effective preventive strategy, dramatically reducing mortality rates, hospital admissions, and treatment costs in both developed and developing countries. The WHO recommends routine rotavirus immunization in national immunization programs, and the results have been compelling: countries that introduced the vaccine saw hospitalizations due to rotavirus decrease by over 80%. Current vaccines-such as Rotarix, RotaTeq, and newer heat-stable versions-are primarily oral and well-tolerated in infants. Furthermore, new entrants are aiming to improve coverage in rural and remote areas with drop-in cold chain alternatives. The critical importance of rotavirus vaccination lies not just in prevention, but in averting strain on pediatric healthcare infrastructure globally.

Are Next-Gen Formulations and Broader Access Models Driving Global Immunization?

New vaccine technologies and expanded manufacturing capabilities are reshaping the rotavirus immunization landscape. Heat-stable formulations that require minimal cold chain storage are being piloted for deployment in remote regions across Africa and Southeast Asia. Additionally, single-dose and neonatal formulations are under development to streamline scheduling and boost compliance. The rise of public-private partnerships, such as those fostered by Gavi, the Vaccine Alliance, is facilitating widespread, subsidized distribution in low-income nations. Equally important is the emergence of local manufacturers in India, China, and Brazil who are producing cost-effective generics and biosimilars, reducing dependency on Western pharma giants. Vaccine coverage is now increasing not only due to logistics but also due to targeted education campaigns aimed at caregivers and community health workers. The combination of scientific advancement and equitable access strategies is setting the stage for a broader and more sustained decline in rotavirus-related morbidity.

Can Surveillance Data and Real-World Outcomes Influence Vaccine Evolution?

Real-world efficacy studies and ongoing epidemiological surveillance are proving essential in refining vaccine strategies for rotavirus. Strain diversity is a known challenge-especially in regions where multiple serotypes co-circulate-and studies have revealed varying degrees of protection across different geographies. This has prompted development of region-specific vaccine blends and enhanced bivalent formulations. Moreover, integration of rotavirus vaccines into digital health registries has allowed for better outcome tracking, adverse event monitoring, and adherence analysis. Longitudinal data shows herd immunity benefits, with even unvaccinated populations experiencing reduced infection rates in high-coverage areas. These insights are helping vaccine makers improve targeting, while allowing governments to reallocate health budgets based on demonstrated impact. Combined with advances in genomic sequencing of rotavirus strains, real-world data is becoming a cornerstone of next-gen vaccine innovation.

What’s Driving Global Expansion of Rotavirus Vaccines Across Health Systems?

The growth in the global rotavirus vaccines market is driven by several factors, notably expanded immunization funding, regional manufacturing capabilities, and vaccine technology innovation. Government mandates for pediatric immunization and WHO prequalification of new vaccine variants are accelerating market access globally. Rising birth rates in Africa and South Asia, coupled with increased awareness among parents and healthcare workers, are strengthening demand. Technological improvements-like thermostable and single-dose oral formulations-are improving logistical feasibility and reducing costs. Subsidized pricing and multilateral procurement frameworks through UNICEF and Gavi have significantly increased vaccine availability in resource-poor settings. Additionally, local clinical trials and approvals in high-burden countries are making rollouts faster and more culturally acceptable. With public health systems focusing on early-life disease prevention, rotavirus vaccines are becoming a staple in routine immunization schedules worldwide.

SCOPE OF STUDY:

The report analyzes the Rotavirus Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb, Other Types); End-Use (Hospitals & Clinics, Academic & Research, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Bharat Biotech
  • Bio Farma
  • Biological E. Limited
  • Cadila Healthcare (Zydus Cadila)
  • Center for Research and Production of Vaccines and Biologicals (POLYVAC)
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • Indian Immunologicals Limited
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vabiotech
  • Valneva SE

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP35690

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Rotavirus Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Burden of Pediatric Diarrheal Diseases Drives Demand for Rotavirus Vaccination
    • Expanded Immunization Programs in Emerging Economies Propel Market Growth
    • World Health Organization Recommendations Strengthen the Business Case for Global Rollouts
    • Inclusion of Rotavirus Vaccines in National Immunization Schedules Expands Addressable Market
    • GAVI and UNICEF Funding Initiatives Generate Access Opportunities in Low-Income Regions
    • Advancements in Cold Chain Logistics Sustain Growth in Global Distribution
    • Rising Awareness Campaigns Around Infant Health Spur Vaccine Adoption
    • Improved Efficacy and Longer Duration of Protection Drive Preference for New Formulations
    • Ongoing Research on Combination Vaccines Throws the Spotlight on Product Innovation
    • Efforts to Reduce Child Mortality Rates Reinforce Market Demand
    • Entry of Low-Cost Manufacturers Boosts Supply in Price-Sensitive Markets
    • Regulatory Approvals of New Vaccine Variants Accelerate Market Penetration
    • Public-Private Partnerships Enhance Vaccine Delivery Infrastructure
    • Surveillance Data and Disease Burden Analytics Drive Policy and Procurement Decisions
    • Pandemic-Driven Focus on Immunization Resilience Creates Opportunities for Vaccine Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rotavirus Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Rotarix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Rotateq by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Rotavin-M1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Lanzhou Lamb by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Academic & Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Rotavirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Rotavirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!